Chlorphenoxamine

Summary

Chlorphenoxamine (CHEMBL2110774) is an approved small molecule (ATC R06AA06); indicated across 2 conditions including allergic disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: R06AA06 (+2 more)
• Indications: 2 conditions
• Chemistry: 303.8 Da · C18H22ClNO

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2110774
Name	Chlorphenoxamine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	6475
ATC	R06AA06, D04AA34, R06AA56
Molecular formula	C18H22ClNO
Molecular weight	303.8
InChIKey	KKHPNPMTPORSQE-UHFFFAOYSA-N

SMILES: CC(C1=CC=CC=C1)(C2=CC=C(C=C2)Cl)OCCN(C)C

IUPAC name: 2-[1-(4-chlorophenyl)-1-phenylethoxy]-N,N-dimethylethanamine

Also known as: Chlorphenoxamine, Clorfenoxamina, CHLORPHENOXAMINE, C-172

Parent form; salt/anhydrous children: CHEMBL2105980

Patent coverage: 370 distinct patent families (1,326 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
allergic disease	4	MONDO:0005271	MONDO:0005271

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).